Tsuchimoto Akihiro, Tanaka Shigeru, Kitamura Hiromasa, Hiyamuta Hiroto, Tsuruya Kazuhiko, Kitazono Takanari, Nakano Toshiaki
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Clin Exp Nephrol. 2022 Nov;26(11):1100-1110. doi: 10.1007/s10157-022-02250-9. Epub 2022 Aug 4.
Hypertension is an important prognostic predictor in patients with chronic kidney disease (CKD), and the recommended target blood pressure has been continuously revised. This study aimed to reveal the current antihypertensive practices in Japanese patients with CKD.
In the Fukuoka Kidney disease Registry, we extracted 3664 non-dialysis-dependent patients with CKD. Apparent treatment-resistant hypertension (aTRH) was defined as a failure of blood-pressure control treated with three antihypertensive medication classes or a treatment with ≥ 4 classes regardless of blood pressure. The blood-pressure control complied with the target blood pressure recommended by the KDIGO 2012 guideline.
The median age of the patients was 67 years, body mass index (BMI) was 23 kg/m, and estimated glomerular filtration rate (eGFR) was 40 mL/min/1.73 m. The number of patients with unachieved blood-pressure control was 1933, of whom 26% received ≥ 3 classes of antihypertensive medications. The first choice of medication was renin-angiotensin system inhibitors, followed by calcium-channel blockers. The rate of thiazide use was low in all CKD stages (3-11%). The prevalence of aTRH was 16%, which was significantly associated with BMI (odds ratio [95% confidence interval] per 1-standard deviation change, 1.38 [1.25-1.53]), decreased eGFR (1.87 [1.57-2.23]), as well as age, diabetes mellitus, and chronic heart disease.
Renal dysfunction and obesity are important risk factors of aTRH. Even under nephrologist care, most patients were treated with insufficient antihypertensive medications. It is important to prescribe sufficient classes of antihypertensive medications, including diuretics, and to improve patients' lifestyle habits.
高血压是慢性肾脏病(CKD)患者重要的预后预测指标,推荐的血压目标值也在不断修订。本研究旨在揭示日本CKD患者当前的降压治疗情况。
在福冈肾脏病登记处,我们提取了3664例非透析依赖的CKD患者。显性治疗抵抗性高血压(aTRH)定义为使用三类降压药物治疗后血压控制不佳,或无论血压情况使用≥4类药物治疗。血压控制符合KDIGO 2012指南推荐的目标血压。
患者的中位年龄为67岁,体重指数(BMI)为23kg/m²,估计肾小球滤过率(eGFR)为40mL/min/1.73m²。血压未得到控制的患者有1933例,其中26%接受了≥3类降压药物治疗。首选药物是肾素-血管紧张素系统抑制剂,其次是钙通道阻滞剂。在所有CKD阶段,噻嗪类药物的使用率都很低(3-11%)。aTRH的患病率为16%,与BMI(每1个标准差变化的比值比[95%置信区间],1.38[1.25-1.53])、eGFR降低(1.87[1.57-2.23])以及年龄、糖尿病和慢性心脏病显著相关。
肾功能不全和肥胖是aTRH的重要危险因素。即使在肾脏病专家的治疗下,大多数患者的降压药物治疗仍不足。开具足够种类的降压药物,包括利尿剂,并改善患者的生活习惯很重要。